Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Asthma
Verus Pharmaceuticals Announces Divestiture of Pediatric Asthma Development Programs to AstraZeneca
October 8th, 2007
Verus Pharmaceuticals, Inc., a pediatric-oriented specialty pharmaceutical company, announced that AstraZeneca, one of the world's leading pharmaceutical companies, has acquired its pediatric asthma development programs. Included in the transaction are the North American rights to a Captisol(R) enabled budesonide solution (controller medication), a proprietary short-acting beta agonist solution (rescue medication), a customized version of eFlow(R) (novel nebulizer delivery device) for use with both medications, and other intellectual property and related assets from Verus. Under the terms of the agreement, Verus is to receive an upfront payment of $30 million,...
Source: Biotech Business Week (2007-10-08)
|
